InvestorsObserver
×
News Home

How Does Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rank Against the Competition?

Wednesday, April 08, 2020 10:50 AM | InvestorsObserver Analysts

Mentioned in this article

How Does Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rank Against the Competition?

Alnylam Pharmaceuticals, Inc. (ALNY) is near the top in its industry group according to InvestorsObserver. ALNY gets an overall rating of 60. That means it scores higher than 60 percent of stocks. Alnylam Pharmaceuticals, Inc. gets a 67 rank in the Biotechnology industry. Biotechnology is number 14 out of 148 industries.

Overall Score - 60
ALNY has an Overall Score of 60. Find out what this means to you and get the rest of the rankings on ALNY!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 60 would rank higher than 60 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Alnylam Pharmaceuticals, Inc. Stock Today?

Alnylam Pharmaceuticals, Inc. (ALNY) stock is lower by -2.3% while the S&P 500 is unchanged 0% as of 10:45 AM on Wednesday, Apr 8. ALNY has fallen -$2.52 from the previous closing price of $109.52 on volume of 206,730 shares. Over the past year the S&P 500 is lower by -7.60% while ALNY is higher by 20.35%. ALNY lost -$8.11 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Alnylam Pharmaceuticals, Inc. click here.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App